Marshall Wace North America’s Genomic Health, Inc. GHDX Stock Holding History

Marshall Wace North America’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-23,600	Closed	-$1.37M	–	1675
2019 Q2	$1.37M	Buy	+23,600	New	+$1.4M	0.01%	659
2018 Q3	–	Sell	-12,187	Closed	-$614K	–	1583
2018 Q2	$614K	Buy	+12,187	New	+$484K	﹤0.01%	1036
2017 Q4	–	Sell	-15,521	Closed	-$497K	–	1739
2017 Q3	$497K	Buy	+15,521	New	+$490K	﹤0.01%	1076
2017 Q2	–	Sell	-27,248	Closed	-$845K	–	1528
2017 Q1	$845K	Buy	+27,248	New	+$806K	0.01%	730

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Marshall Wace North America's GHDX Position: Q3 2019 in Review

Marshall Wace North America sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 23,600 shares — an estimated $1.37M sold.

Marshall Wace North America first reported a position in GHDX in Q1 2017 and held it in 4 quarters. The position peaked at $1.37M in Q2 2019. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.

Marshall Wace North America reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
Marshall Wace North America sold 23,600 Genomic Health, Inc. shares in Q3 2019, an estimated $1.37M.
Marshall Wace North America first reported a position in Genomic Health, Inc. in Q1 2017 and held it in 4 quarters.
Marshall Wace North America's Genomic Health, Inc. position peaked at $1.37M in Q2 2019.
221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.

Based on Marshall Wace North America's 13F filing for Q3 2019, filed 14 Nov 2019.